

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Box SEQUENCE, Director – U.S. Patent and Trademark Office, Washington, D.C. 20231 orthis 6th day of October, 2000.

By

(Signature of person mailing)

Janice M. Denison

(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lee Harland

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Herewith : Group Art Unit: To be assigned

TITLE: Novel Polypeptide

Box SEQUENCE Director – U.S. Patent and Trademark Office Washington, D.C. 20231

## STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Date: 10-6-2000

Deborah A. Martin Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-1821